

- research and teaching by, 7
social media use by, 17e-3
as student, 7
trainee, ethical issues for, 17e-4
virtue ethics and, 17e-2
working hours of, 7, 12e-1, 17e-3
Physician-assisted suicide, 67–68, 67t
Physician-induced demand, 21
Physician Orders for Life-Sustaining Treatment (POLST), 58
Physician-patient relationship, 1, 4–5
racial/ethnic factors in communication, 16e-3–4, 16e-4f
trust within, 16e-4–5
Physiology, 87e-1
Physostigmine
for anticholinergic overdose, 473e-5, 473e-8t, 1776
for belladonna alkaloid overdose, 473e-8t
for mushroom/plant poisoning, 473e-9t
overdosage/poisoning with, 473e-10t
Phytohemagglutinin (PHA), 83e-1
PI3K (phosphatidylinositol-3-kinase), 102e-6
PI3K/AKT pathway
in cancer, 102e-10
in endometrial cancer, 596
in head and neck cancer, 503
in melanoma, 496, 496f
PI3P, 1106
Pian. *See* Yaws
Piano-key movement, ulnar styloid, 35
PIC3CD gene, 2111
Pica, 2719
Pick's disease, 444e-8f, 2604, 2604f, 2605f
Picobirnaviruses, 1286f, 1289
Picornaviruses
gene expression and replication in, 214e-4
human respiratory syncytial virus, 1205. *See also* Human respiratory syncytial virus (HRSV) infections
rhinoviruses, 1202–1203. *See also* Rhinovirus infections
structure of, 214e-2t, 214e-3f
“Picture frame” vertebra, 426e-2
PID. *See* Pelvic inflammatory disease (PID)
Piebaldism, 357t, 358t, 359
PIEZO1 gene mutations, 653, 653t
PIG-A gene mutations, 664
Pigbel (enteritis necroticans), 991
Pigeon chest (pectus carinatum), 1443, 2512
Pigmented pretibial papules, 2429
Pigmented villonodular synovitis (PVNS), 2246, 2247f
Pigment stones, 2078, 2078t
PIK3A gene mutations, 101e-2t
PIK3CA gene mutations
in Cowden's syndrome, 2344
in lung cancer, 507t, 509, 509t
Pili (fimbriae), bacterial, 145e-2, 145e-2t
of *B. Pertussis*, 1021
of *E. coli*, 145e-2, 145e-2f
of enterococci, 972
of *N. gonorrhoeae*, 1003
of *P. aeruginosa*, 1043, 1043t
of *S. pneumoniae*, 947, 947f
type IV, 145e-2, 145e-8
Pill esophagitis, 257, 1910
Pilocarpine
for acute angle-closure glaucoma, 200
in diagnosis of tonic pupil, 197
overdosage/poisoning with, 473e-10t
for xerostomia, 241
Piloosebaceous unit, 331
Pimecrolimus, 345, 354t
Pimozide, 246e-3t, 2751
Pinch purpura, 365
Pindolol, 473e-9t, 1589t
Pineal region tumors, 602
Pinguecula, 199
PINK1 gene mutations, 444e-9, 2092, 2613
“Pink puffers,” 1704
Pinna. *See* Ear
Pinta, 207e-2–3, 207e-2f, 207e-2t
Pintides, 207e-3
Pinworm. *See* *Baylisascaris procyonis* infections; *Enterobius vermicularis*/enterobiasis (pinworm)
Pioglitazone, 2057, 2414t, 2415
Piperacillin
adverse effects of, 727t
for burn-wound infections, 166e-3
indications for, 938
for otitis externa, 229
resistance to, 938
Piperacillin-tazobactam
for actinomycosis, 1091t
for anaerobic bacterial infections, 1101t
for community-acquired pneumonia, 808t
for febrile neutropenia, 491
for gram-negative bacterial infection, 1026
for health care-associated pneumonia, 767t, 812t
indications for, 938–939, 940t
for intraabdominal infections, 767t
for osteomyelitis, 840t, 841t
for *P. aeruginosa* infections, 808t, 1045t
for peritonitis, 847
resistance to, 940t, 1101
for sepsis/septic shock, 1757t
for septic shock, 767t, 780t
Piperazine, 246e-6t, 246e-11–12
Piracetam, 2623
Piranha bite-wound, 167e-1
Pirfenidone, 2164
Piroxicam
adverse effects of, 356, 389t
for colorectal cancer prevention, 477
drug interactions of, 43
for paroxysmal hemichorea, 2596
Piry virus, 1310t
Pit-1
in anterior pituitary development, 401e-1, 401e-1t, 2256
in congenital hypothyroidism, 2284t
in growth hormone deficiency, 2258
Pitavastatin, 2448t
Pitting, 410
Pitting edema, 251. *See also* Edema
Pituitary apoplexy, 207, 2257, 2325t
Pituitary axes, 401e-2f
Pituitary disorders
anterior
insufficiency. *See* Hypopituitarism
tumors. *See* Pituitary tumors (adenomas)
IgG4-related, 391e-1t
posterior
diabetes insipidus. *See* Diabetes insipidus (DI)
hypodipsic hypernatremia. *See* Hypodipsic hypernatremia
Pituitary gland
anatomy of, 401e-1, 401e-2
development of, 401e-1, 401e-1t
dysplasia, 2255–2256
hormones produced by. *See* Pituitary hormones; *specific hormones*
insufficiency of. *See* Hypopituitarism
tests of function of, 2258t
Pituitary hormones, 401e-1. *See also specific types*
expression and regulation of, 401e-1t, 2274
in ovarian function regulation, 2376–2377, 2377f
secretion of, 401e-1, 401e-2f
Pituitary snuff taker's lung, 1681t
Pituitary tumors (adenomas), 2265
ACTH-producing. *See* Cushing's syndrome
classification of, 603, 2265, 2265t
clinical features of, 2261–2262, 2261t, 2339
etiology of, 2265
familial syndromes of, 2265–2266, 2265t, 2340
gonadotropin-producing, 2273–2274
histologic evaluation in, 2262
hormone-excess syndromes due to, 2265
hypogonadotropic hypogonadism and, 2365
laboratory investigation of, 2262, 2262t
local mass effects of, 2261–2263
in MEN 1, 2265–2266, 2265t, 2336t, 2339
MRI in, 2262, 2262f
nonfunctioning, 603, 2273–2274, 2274f
ocular signs in, 198, 207
ophthalmologic evaluation in, 2262t
pathogenesis of, 2265
secondary adrenal insufficiency and, 2325t
treatment of, 603, 2262–2264, 2263f, 2339
TSH-secreting, 2274, 2298
Pit viper bite, 2734, 2734f, 2736t, 2738
Pityriasis rosea, 349
clinical features of, 347t
distribution, 341t, 342f, 347t
erythroderma, 353t
lesion characteristics, 349
morphology, 341t
papulosquamous lesions, 353
patches on trunk, 76e-3f, 349f
differential diagnosis of, 134
histologic features of, 347t
treatment of, 349
Pityriasis rubra pilaris, 354t
Pivmecillinam, 866, 867t, 1058t
Pizotifen, 2594t
PKAN (pantothenate kinase-associated neurodegeneration), 2626
PKD (paroxysmal kinesigenic dyskinesia), 2624–2625
PKD-1 gene mutations, 1850, 1851
PKD-2 gene mutations, 1850, 1851
PKHD1 gene mutations, 1853
Placebo effect, 89, 90f
Placental stem cells, 92e-1
Plague, 1070. *See also* *Yersinia pestis*
in bioterrorism, 261e-3–4
bubonic, 261e-4, 1072, 1072f
case definitions of, 1073t
clinical features of, 261e-4–5, 261e-5t
diagnosis of, 150e-8, 261e-5t, 1073–1074, 1074f
epidemiology of, 151e-8f, 1070–1071, 1071f
global considerations in, 1070–1071, 1071f, 1073
meningeal, 1072
multidrug-resistant, 261e-6
pathogenesis of, 1071–1072
pharyngitis, 1072–1073
pneumonic, 261e-4, 261e-5t, 1072, 1073f
prevention of, 261e-5t, 261e-6, 1075–1076, 1075t
septicemic, 261e-4–5, 781, 1072
treatment of, 261e-5–6, 261e-5t, 1074–1075, 1074t
Plague vaccine, 261e-6, 1075–1076
PLAID (PLCγ-associated antibody deficiency and immune dysregulation), 2113
Plan-Do-Check-Act cycle, 12e-3f
Planktonic cells, 145e-4
Plantar fasciitis, 2249–2250
Plantar reflex, 2538
Plantar warts, 351
Plaque
atherosclerotic. *See* Atherosclerosis, pathogenesis of
dental, 46e-4f, 236, 1097
neuritic, in AD, 2599, 2600f
Plaque (skin lesion), 127, 339t
Plaques jaunes, 457e-1
Plasma
derivatives, 138e-2, 138e-3
fresh-frozen. *See* Fresh-frozen plasma
O₂ concentration, 1748t
platelet-rich, 138e-2
Plasma cell(s), 81e-11f
Plasma cell disorders, 710
acid-base disorders in, 317
amyloidosis. *See* Amyloidosis
genetic considerations in, 710, 711f
heavy chain disease, 718–719
multiple myeloma. *See* Multiple myeloma
paraproteinemia in, 404
pathophysiology of, 710–712, 712f
proteinuria in, 293
Waldenström's macroglobulinemia. *See* Waldenström's macroglobulinemia